26P Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin

F Miglietta,G Zarrilli,D Massa,G Griguolo,M Fassan,M Bottosso,C.A Giorgi,T Giarratano,G Vernaci,M Cesarotto,M.C Guarascio,V Guarneri,M.V Dieci

doi:10.1016/j.annonc.2022.03.041

26P Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin

F Miglietta, G Zarrilli + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2022.03.041

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: May 1, 2022

Affiliation: Istituto Oncologico Veneto, University of Padua, Istituti di Ricovero e Cura a Carattere Scientifico

#Pathologic Complete Response #Standard Neoadjuvant Chemotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In patients with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy (NACT), higher tumor-infiltrating lymphocytes (TILs) strongly correlate with increased rates of pathologic complete response (pCR) and improved survival. The aim of the present work is to investigate the changes of TIL levels from baseline biopsy to residual disease (RD) in TNBC patients failing to achieve pCR after standard NACT with anthracycline-taxane (A-T) +/- carboplatin (Cb).

Full Text